Generalised longitudinal formulation Sample Clauses

Generalised longitudinal formulation. Cognitive theory posits the particular content of intrusions and appraisals relate to idiosyncratic assumptions or beliefs shaped by early experiences, which may become more salient following stressful life events. As it was clear Xxxxxx’s OCD had multiple and shifting manifestations, including intrusive images, urges and doubts which led to compulsive neutralising, checking and washing a longitudinal formulation (Xxxx, 1979) was developed with Xxxxxx to aid her understanding of her OCD (figure 4). This helped Xxxxxx identify which early experiences (e.g. her father being ‘obsessed’ with germs and cleanliness) and critical incidents (e.g. being subject to sexual abuse from her older cousin when they were children) may have made her more vulnerable to developing OCD. It also helped highlight key assumptions (e.g. belief in karma) that were likely to feed into her intrusions and resultant misinterpretation of the significance of responsibility. Importantly the longitudinal formulation supported Xxxxxx to generalize, so that she could see all of her separate obsessions and compulsions as part of the same OCD problem. This was particularly valuable for Xxxxxx as this understanding minimised her concerns about her OCD manifesting differently after treatment, by providing her with a structure to manage this.
AutoNDA by SimpleDocs

Related to Generalised longitudinal formulation

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Outputs 11. The objectives and outcomes of this Agreement will be achieved by:

  • Technical Characteristics The Participating Generator has provided to the CAISO in Schedule 1 the required information regarding the capacity and operating characteristics of each of the Generating Units listed in that schedule. Pursuant to Sections 8.9 and 8.10 of the CAISO Tariff, the CAISO may verify, inspect and test the capacity and operating characteristics provided in Schedule 1.

  • EODUF Packing Specifications 7.3.1 The data will be packed using ATIS EMI records. A pack will contain a minimum of one (1) message record or a maximum of ninety-nine thousand nine hundred and ninety-nine (99,999) message records plus a pack header record and a pack trailer record. One transmission can contain a maximum of ninety-nine (99) packs and a minimum of one (1) pack.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • ODUF Packing Specifications 6.3.1 The data will be packed using ATIS EMI records. A pack will contain a minimum of one (1) message record or a maximum of ninety-nine thousand nine hundred and ninety-nine (99,999) message records plus a pack header record and a pack trailer record. One transmission can contain a maximum of ninety-nine (99) packs and a minimum of one (1) pack.

  • Reformulation of Products As of the Effective Date, and continuing thereafter, Products that Xxxxx directly manufactures, imports, distributes, sells, or offers for sale in California shall either: (a) be Reformulated Products pursuant to § 2.2, below; or (b) be labeled with a clear and reasonable exposure warning pursuant to §§ 2.3 and 2.4, below. For purposes of this Settlement Agreement, a “Reformulated Product” is a Product that is in compliance with the standard set forth in § 2.2, below. The warning requirement set forth in §§ 2.3 and 2.4 shall not apply to any Reformulated Product.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!